stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Book value per share
Lakefront Biotherapeutics - Sponsored ADR's book value per share at the end of fiscal 2025 was 55.6×, up 16.8% from 47.6× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 0.0×. Over the past ten years it has ranged from 11.4× (fiscal 2015) to 55.9× (fiscal 2019); the current reading is higher than 91% of that period. Lakefront Biotherapeutics - Sponsored ADR ranks 477th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 55.6× | 16.79% |
| FY2024 | 47.6× | 3.59% |
| FY2023 | 45.9× | 13.37% |
| FY2022 | 40.5× | (15.16%) |
| FY2021 | 47.7× | 1.86% |
| FY2020 | 46.9× | (16.15%) |
| FY2019 | 55.9× | 103.15% |
| FY2018 | 27.5× | 19.03% |
| FY2017 | 23.1× | 25.82% |
| FY2016 | 18.4× | 61.84% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 57.8× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 34 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 15.1× |
| SEPN Septerna, Inc. compare | 8.6× |
| VCEL Vericel Corporation compare | 7.5× |
| VERA Vera Therapeutics, Inc. compare | 5.7× |
| AUPH Aurinia Pharmaceuticals Inc compare | 4.9× |
| IMNM Immunome, Inc. compare | 4.6× |
| ZYME Zymeworks Inc. compare | 1.1× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | 0.0× |
| BHVN Biohaven Ltd. compare | −0.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement